Regencell Bioscience Holdings (RGC) Cash & Equivalents Growth (3y) (2023 - 2024)
Regencell Bioscience Holdings (RGC) Cash & Equivalents Growth (3y) (2023 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.92 Bn | 42.96 Bn | - | 21.81% |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.53 Bn | 2.15 Bn | 11.05% |
| 3 | Zoetis | 31.74 Bn | 30.06 Bn | 1.05 Bn | -4.92% |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.87 Bn | 5.10 Bn | 7.80% |
| 5 | United Therapeutics | 22.22 Bn | 19.56 Bn | 683.80 Mn | 19.10% |
| 6 | Viatris | 18.71 Bn | 17.83 Bn | 1.46 Bn | 12.11% |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 27.55% |
| 8 | Elanco Animal Health | 11.80 Bn | 11.27 Bn | 798.00 Mn | 13.03% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | 32.82% |
| 10 | Regencell Bioscience Holdings | 2.76 Bn | 2.76 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 268.01% |
| Jun 30, 2023 | 59.32% |